Literature DB >> 17608356

Management of newly diagnosed single brain metastasis using resection and permanent iodine-125 seeds without initial whole-brain radiotherapy: a two institution experience.

Elias Dagnew1, Jeffrey Kanski, Michael W McDermott, Penny K Sneed, Christopher McPherson, John C Breneman, Ronald E Warnick.   

Abstract

OBJECT: Whole-brain radiotherapy (WBRT) after resection of a single brain metastasis can cause long-term radiation toxicity. The authors evaluated the efficacy of resection and placement of 125I seeds (without concomitant WBRT) for newly diagnosed single brain metastases.
METHODS: In a retrospective review from two institutions (1997-2003), 15 women and 11 men (mean age 55 years) with single brain metastasis underwent gross-total resection and placement of permanent low-activity 125I seeds. Primary systemic cancer sites varied. Patients were monitored clinically and radiographically. With neuroimaging evidence of local recurrence or new distant metastasis, further treatment was administered at the physician's discretion. By the median follow-up evaluation (12 months), the local tumor control rate was 96%. Distant metastases occurred in three patients within 3 months, suggesting synchronous metastasis, and in six patients more than 3 months after treatment, indicating metachronous metastasis. Treatment in these cases included radiosurgery in seven patients, WBRT in two, and resection together with 125I seed placement in one. Two patients who suffered radiation necrosis required operative intervention (lesion diameter > 3 cm, total activity > 40 mCi). All 26 patients who had been treated using resection and placement of 125I seeds had a stable or an improved Karnofsky Performance Scale score. At the last review, nine of 16 living patients showed no evidence of treatment failure. The median actuarial survival rate was 17.8 months (Kaplan-Meier method).
CONCLUSIONS: Permanent 125I brachytherapy applied at the initial operation without WBRT provided excellent local tumor control. Local control and patient survival rates were at least as good as those reported for resection combined with WBRT. Although the authors noted a higher incidence of distant metastases compared with that reported in other studies of initial WBRT, these metastases were generally well controlled with a combination of surgery, stereotactic radiosurgery, and, less often, WBRT. Twenty-four patients (92%) never required WBRT, thus avoiding potential long-term radiation-induced neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608356     DOI: 10.3171/foc.2007.22.3.4

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  18 in total

1.  Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial.

Authors:  Anthony Pham; Menachem Z Yondorf; Bhupesh Parashar; Ronald J Scheff; Susan C Pannullo; Rohan Ramakrishna; Philip E Stieg; Theodore H Schwartz; A Gabriella Wernicke
Journal:  J Neurooncol       Date:  2015-12-09       Impact factor: 4.130

2.  The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors.

Authors:  A Gabriella Wernicke; Menachem Z Yondorf; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao; John A Boockvar; Susan Pannullo; Philip Stieg; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

3.  Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases.

Authors:  A Gabriella Wernicke; Menachem Z Yondorf; Luke Peng; Samuel Trichter; Lucy Nedialkova; Albert Sabbas; Fridon Kulidzhanov; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao; Paul Christos; Ilhami Kovanlikaya; Susan Pannullo; John A Boockvar; Philip E Stieg; Theodore H Schwartz
Journal:  J Neurosurg       Date:  2014-05-02       Impact factor: 5.115

4.  Surgical Technique and Clinically Relevant Resection Cavity Dynamics Following Implantation of Cesium-131 (Cs-131) Brachytherapy in Patients With Brain Metastases.

Authors:  A Gabriella Wernicke; Stefanie P Lazow; Shoshana Taube; Menachem Z Yondorf; Ilhami Kovanlikaya; Dattatreyudu Nori; Paul Christos; John A Boockvar; Susan Pannullo; Philip E Stieg; Theodore H Schwartz
Journal:  Oper Neurosurg (Hagerstown)       Date:  2015-08-01       Impact factor: 2.703

5.  Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.

Authors:  Christopher M McPherson; Margie Gerena-Lewis; John C Breneman; Ronald E Warnick
Journal:  J Neurooncol       Date:  2012-04-01       Impact factor: 4.130

Review 6.  Controversies concerning the application of brachytherapy in central nervous system tumors.

Authors:  Bo-Lin Liu; Jin-Xiang Cheng; Xiang Zhang; Wei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

7.  Management of newly diagnosed single brain metastasis with surgical resection and permanent I-125 seeds without upfront whole brain radiotherapy.

Authors:  Michael J Petr; Christopher M McPherson; John C Breneman; Ronald E Warnick
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 8.  Current advances in understanding and managing secondary brain metastasis.

Authors:  Radhika Dasararaju; Amitkumar Mehta
Journal:  CNS Oncol       Date:  2013-01

9.  Modern treatment of cerebral metastases: Integrated Medical Learning(SM) at CNS 2007.

Authors:  Michael A Vogelbaum; Anthony L Asher; Douglas Kondziolka; Nicholas M Boulis; Nathan R Selden; Brian L Hoh; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

10.  The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.

Authors:  Jeffrey J Olson; Nina A Paleologos; Laurie E Gaspar; Paula D Robinson; Rachel E Morris; Mario Ammirati; David W Andrews; Anthony L Asher; Stuart H Burri; Charles S Cobbs; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.